State of Illinois is investigating pricing of Novo Nordisk's diabetes products

The Danish pharmaceutical company says it has received a civil investigative demand from the Illinois attorney general’s office, meaning Novo Nordisk will have to turn over required documents.

Photo: Mads Claus Rasmussen//

On June 23, Novo Nordisk found out that the attorney general of the state of Illinois is looking into the company’s trade practices, in particular relating to its pricing of diabetes products Victoza and Ozempic alongside some insulins, when it received a so-called civil investigative demand, or CID.

The Danish pharmaceutical firm said this in its recently publicized financial report for the first half of the year, also stating that it is complying with the CID, which is a discovery tool used by authorities in the US to get their hands on relevant documentation.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs